Literature DB >> 16405612

Therapy of paraneoplastic pemphigus with Rituximab: a case report and review of literature.

Ma Barnadas1, E Roe, S Brunet, P Garcia, P Bergua, L Pimentel, L Puig, A Francia, R García, C Gelpí, J Sierra, P Coll, A Alomar.   

Abstract

Paraneoplastic pemphigus (PNP) is an autoimmune blistering disease with poor prognosis when associated with malignant neoplasm. We report the case of a patient with PNP associated with a CD20+ non-Hodgkin follicular lymphoma who was treated with Rituximab plus corticosteroids and short courses of cyclosporin. One and a half years after Rituximab therapy, oral ulcerations had cleared and oral methylprednisolone was slowly tapered down without further recurrences. In the course of the disease, the patient developed sepsis due to Listeria monocytogenes and viral infections by human herpes virus 1 and 3. At the end-stage of the disease she developed a cutaneous infection from Mycobacterium chelonae. The patient died 2 years and 7 months after the onset of PNP. Rituximab may be useful for PNP therapy, but further studies are necessary to confirm this hypothesis.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16405612     DOI: 10.1111/j.1468-3083.2005.01345.x

Source DB:  PubMed          Journal:  J Eur Acad Dermatol Venereol        ISSN: 0926-9959            Impact factor:   6.166


  9 in total

Review 1.  Pemphigus: a brief review.

Authors:  Richard W Groves
Journal:  Clin Med (Lond)       Date:  2009-08       Impact factor: 2.659

2.  Listeriosis in a Metropolitan Hospital: Is Targeted Therapy a Risk Factor for Infection?

Authors:  Fanfan Xing; Simon K F Lo; Susanna K P Lau; Patrick C Y Woo
Journal:  Front Med (Lausanne)       Date:  2022-04-29

3.  A case report of paraneoplastic pemphigus associated with esophageal squamous cell carcinoma.

Authors:  Jin Hyun Cho; Nam Jun Kim; Sung Min Ko; Chunghun Kim; Hee Kyung Ahn; Jina Yun; Yeon Hee Park
Journal:  Cancer Res Treat       Date:  2013-03-31       Impact factor: 4.679

Review 4.  Rituximab in treatment-resistant autoimmune blistering skin disorders.

Authors:  Enno Schmidt; Eva-Bettina Bröcker; Matthias Goebeler
Journal:  Clin Rev Allergy Immunol       Date:  2008-02       Impact factor: 8.667

5.  Rituximab therapy in a case of pemphigus vulgaris triggering herpes simplex infection at varied sites.

Authors:  Kiran K Chotaliya; Richa Gupta; Yogesh S Marfatia
Journal:  Indian Dermatol Online J       Date:  2015 Nov-Dec

Review 6.  Pemphigus: Current and Future Therapeutic Strategies.

Authors:  Dario Didona; Roberto Maglie; Rüdiger Eming; Michael Hertl
Journal:  Front Immunol       Date:  2019-06-25       Impact factor: 7.561

7.  Paraneoplastic pemphigus: a clinical, laboratorial, and therapeutic overview.

Authors:  Celina Wakisaka Maruta; Denise Miyamoto; Valeria Aoki; Ricardo Gomes Ribeiro de Carvalho; Breno Medeiros Cunha; Claudia Giuli Santi
Journal:  An Bras Dermatol       Date:  2019-10-17       Impact factor: 1.896

8.  Evaluation of cutaneous side-effects associated with chemotherapeutic use in oncological patients.

Authors:  Zeynep Utlu; Handan Bilen
Journal:  Postepy Dermatol Alergol       Date:  2021-10-22       Impact factor: 1.837

9.  Effectiveness and side effects of anti-CD20 therapy for autoantibody-mediated blistering skin diseases: A comprehensive survey of 71 consecutive patients from the Initial use to 2007.

Authors:  Jennifer D Peterson; Lawrence S Chan
Journal:  Ther Clin Risk Manag       Date:  2009-03-26       Impact factor: 2.423

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.